A feasibility study of chemosensitivity assay by adhesive tumor cell culture system using biopsy specimens for gastric cancer

J Surg Oncol. 2000 Jun;74(2):141-7. doi: 10.1002/1096-9098(200006)74:2<141::AID-JSO12>3.0.CO;2-X.

Abstract

Background and objectives: The adhesive tumor cell culture system (ATCCS) is known to produce high colony-forming efficiency. We, therefore, studied the feasibility of ATCCS for gastric cancer by use of biopsy specimens and the relationship between the results of ATCCS and histological effects of anticancer drugs.

Methods: Tumor specimens extracted by gastroendoscopic biopsy were sufficient for obtaining the result of sensitivity to at least one drug in 24 out of 30 (80%) patients. Twenty patients were administered 5-fluorouracil (5-FU) for 14 days prior to surgery, and the results of ATCCS were compared with histological changes of the resected specimens.

Results: The histological response rate was found to be 100% (4/4) when the 90% inhibition concentration (IC90) of 5-FU was less than 0.24 microg/ml (sensitive) and was 0% (0/3) when IC90 was greater than 0.40 microg/ml (resistant).

Conclusions: Although lacking in statistical significance, the results suggest that the drug to which the tumor revealed sensitivity in the ATCCS would produce histological effects and the drug to which the tumor was resistant would have no histological effect.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Antimetabolites, Antineoplastic / pharmacology*
  • Antineoplastic Agents / pharmacology
  • Biopsy
  • Cisplatin / pharmacology
  • Doxorubicin / pharmacology
  • Drug Screening Assays, Antitumor
  • Feasibility Studies
  • Female
  • Fluorouracil / pharmacology*
  • Humans
  • Male
  • Middle Aged
  • Mitomycin / pharmacology
  • Sensitivity and Specificity
  • Stomach / pathology
  • Stomach Neoplasms / pathology*
  • Tumor Cells, Cultured / drug effects

Substances

  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents
  • Mitomycin
  • Doxorubicin
  • Cisplatin
  • Fluorouracil